Sentence examples for dose subject from inspiring English sources
The trial used a standard 3 + 3 dose escalation design as previously described, with only the HCQ dose subject to dose-escalation rules.
The study treatment was terminated after 4 weeks; however, patients were allowed to continue on the final dose subject to tolerance and response.
Also CYP2C19 activity was similarly low in both subjects (plasma omeprazole/5-hydroxyomeprazole 4 h post dose; subject 1, 2.79; subject 2, 2.66), albeit still within the lowest quartile of the normal reference range (Fig. 2).
Subject 1 showed clearly subnormal conversion of the probe drugs, whereas observed metabolic capacities of CYP2D6 and CYP3A4 for subject 2 still varied within the lowest normal range (CYP2D6: plasma dextromethorphan/dextrorphan 3 h post dose; subject 1, 5.05; subject 2, 0.68; CYP3A4: oral midazolam clearance (L/hl); subject 1, 10.7; subject 2, 39.7) (Fig. 2).
Within each naltrexone dose, subjects had three alcohol challenge sessions (none, moderate, high) in random order.
Subjects took a randomly assigned second dose of either their previously assigned lasmiditan dose or placebo for rescue or recurrence of migraine if needed (2 to 24 hours post initial dose); subjects randomized to placebo received placebo as the second dose.
After each dose, subjects were instructed to expectorate any sputum present into a Petri dish.
On the highest dose, subjects enrolled for this therapeutic approach had statistically significant improvement in social withdrawal.
At second twitch reappearance, after last rocuronium dose, subjects received sugammadex 2 mg/kg or neostigmine 50 μg/kg plus atropine 10 20 μg/kg, according to randomization.
On days 11, 12, 13 and 14, in addition to vercirnon 500 mg BID, subjects also received the probe compound in the same order as days 1 4.> For each morning dose, subjects were required to fast overnight.
While mean reductions in ipsilateral diaphragm motion were noted following interscalene block in all groups (Table 4), independent of dose, subjects with dyspnea frequently exhibited clinically meaningful ipsilateral diaphragmatic impairment (Relative risk: 2.5; 95%CI: 1.3-4.8; p = 0.042).
